Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
F18 fimbriae are hair-like surface organelles expressed by certain pathogenic strains of Escherichia coli, notably those causing post-weaning diarrhea and edema disease in piglets[1][2]. These fimbriae are assembled via the chaperone-usher pathway and consist of major (FedA), minor (FedE), and tip-adhesin (FedF) subunits, with FedF identified as the key adhesin responsible for binding to glycosphingolipid receptors (specifically ABO blood group type 1 antigens) on the microvilli of porcine small intestinal epithelial cells[1][2][3]. The essential binding domain for adhesion has been mapped to amino acids 60–109 of FedF, with specific residues (His88, Arg117, Lys72, His89) critical for receptor interaction[1][2]. Disruption of this adhesion, either by nanobodies that competitively inhibit the binding site or by antibodies against FedF, blocks bacterial attachment and colonization, highlighting the therapeutic potential of targeting this adhesin[1][3]. The receptor for F18 fimbriae is membrane-associated, requiring specific glycosylation patterns for binding, which explains the host and tissue tropism observed in porcine infections[1][2]. While no drugs are currently approved for clinical use targeting F18 fimbriae, experimental inhibitors (nanobodies, antibodies) have demonstrated efficacy in vitro, establishing F18 fimbriae as a validated antimicrobial target in veterinary medicine[1][3].
Competitive inhibition: Nanobodies such as NbFedF9 bind directly to the carbohydrate-binding site on the FedF adhesin, sterically blocking interaction with host glycan receptors[1]. Conformational disruption: Other nanobodies (e.g., NbFedF6, NbFedF7, NbFedF12) induce conformational changes in the critical D″-E loop of FedF, which is essential for receptor binding, thereby inhibiting adhesion[1]. Antibody-mediated neutralization: Anti-FedF antibodies can inhibit bacterial attachment to host cells, confirming FedF as the functional adhesin[3].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on F18 Fimbriae of Escherichia coli (F18 fimbriae).